Rabin Medical Center, The Pulmonary Institute, Petah Tikva, Israel. Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Rambam Health Care Campus, Haifa, Israel. Affiliated to Technion - Israel Institute of Technology, Haifa, Israel.
Thorac Cardiovasc Surg. 2022 Sep;70(6):520-526. doi: 10.1055/s-0040-1721461. Epub 2021 Jan 21.
Bronchial stenosis is a common complication following lung transplantation. We evaluated long-term associations of the use of self-expandable metal stents (SEMSs) with lung function tests, patient safety, and survival.
A retrospective chart review of 582 lung transplantations performed at our institution between January 2002 and January 2018. Fifty-four patients with SEMSs (intervention group) were matched one-to-one to patients without SEMSs (control group) using propensity score matching for age, sex, the year, and type of transplantation (unilateral/bilateral), and underlying disease. Data regarding long-term lung function and survival were compared between the groups.
During a median follow-up of 54.8 months, the difference in survival between the study groups was not statistically significant ( = 0.2). Following 5, 7.5 and 10 years, values of mean forced expiratory volume in 1 second (FEV1) were comparable between patients with and without SEMSs as follows: 59.5 versus 62.6% ( = 0.2), 55.9 versus 55.0% ( = 0.4), and 63.5 versus 61.9% ( = 0.3), respectively. In the intervention group, a significant increase in the mean FEV1 was observed in 60 days after stent insertion (from 41.9 ± 12.8 to 49.5 ± 16.7% days, < 0.001). Long-term complications following stent insertion included severe bleeding (1.8%), stent fractures (7.4%), stent stenosis (7.4%), stent collapse (3.7%), endobronchial pressure ulcer (1.9%), and stent migration (1.9%).
SEMS insertion is associated with a positive sustained effect on lung function, without increasing long-term mortality. Thus, airway stenosis after lung transplantation can be safely and successfully treated using endobronchial metal stenting, with tight bronchoscopic follow-up and maintenance.
支气管狭窄是肺移植后的常见并发症。我们评估了自膨式金属支架(SEMS)的使用与肺功能测试、患者安全性和生存率之间的长期关联。
对 2002 年 1 月至 2018 年 1 月期间在我院进行的 582 例肺移植患者进行回顾性图表审查。54 例接受 SEMS(干预组)的患者与未接受 SEMS(对照组)的患者进行一对一匹配,匹配因素包括年龄、性别、年份和移植类型(单侧/双侧)以及基础疾病。比较两组患者的长期肺功能和生存率。
在中位随访 54.8 个月期间,两组患者的生存率差异无统计学意义( = 0.2)。在第 5、7.5 和 10 年时,接受 SEMS 治疗的患者与未接受 SEMS 治疗的患者的平均用力呼气量(FEV1)值如下:59.5%比 62.6%( = 0.2),55.9%比 55.0%( = 0.4)和 63.5%比 61.9%( = 0.3)。在干预组中,支架置入后 60 天内 FEV1 平均水平显著增加(从 41.9 ± 12.8%增加到 49.5 ± 16.7%,< 0.001)。支架置入后的长期并发症包括严重出血(1.8%)、支架断裂(7.4%)、支架狭窄(7.4%)、支架塌陷(3.7%)、支气管内压力性溃疡(1.9%)和支架移位(1.9%)。
SEMS 置入与肺功能的持续正效应相关,而不会增加长期死亡率。因此,肺移植后气道狭窄可通过支气管内金属支架置入术安全且成功地治疗,同时需要进行严格的支气管镜随访和维护。